Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
Crossref DOI link: https://doi.org/10.1007/s40273-016-0433-9
Published Online: 2016-07-20
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Davies, Melanie J.
Glah, Divina
Chubb, Barrie
Konidaris, Gerasimos
McEwan, Phil
Funding for this research was provided by:
Novo Nordisk
License valid from 2016-07-20